ISTA Pharmaceuticals
 |
|
| Subsidiary | |
| Industry | Pharmaceuticals |
| Founded | 1992 |
| Headquarters | Irvine, California |
|
Key people
|
Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs Tom Mitro, Vice President, Sales & Marketing |
| Products | Bromday, Bepreve, Xibrom, Istalol, Vitrase |
| Website | www |
Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs
ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. ISTA was acquired by Bausch & Lomb on March 26, 2012.
In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.
On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.
...
Wikipedia